Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Original New Drug Application Approvals by US FDA (1-15 August 2024)

30 Aug 2024

New drug applications approved by US FDA as of 1-15 August 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

30 Aug 2024

Novel GLP-1/GCG receptor agonist shows promise against noncirrhotic MASH with fibrosis

29 Aug 2024

Dual glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptor agonism with cotadutide has shown a signal of benefit in the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis, according to the phase II PROXYMO trial.

29 Aug 2024

AI helps spot HCC sooner

23 Aug 2024 bởi

A novel artificial intelligence (AI) classifier can detect hepatocellular carcinoma (HCC) signatures in routine blood tests up to 1 year before clinical diagnosis, as shown in a study from Hong Kong.

23 Aug 2024

Simple tests predict liver stiffness in people living with HIV, liver disease

22 Aug 2024

A recent study has noted the excellent specificity and negative predictive value of FIB-4 and nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS) in diagnosing advanced fibrosis (AF, bridging fibrosis or cirrhosis) among people living with HIV (PWH).

22 Aug 2024

Jaundice, fluid retention in HCC tied to shorter survival

21 Aug 2024 bởi

The presence of jaundice or fluid retention among patients with hepatocellular carcinoma (HCC) is associated with a shorter overall survival (OS), suggests a Singapore study.

21 Aug 2024

Multiple factors influence risks of cirrhosis, HCC in veterans with MAFLD

17 Aug 2024 bởi

The incidence of cirrhosis and hepatocellular carcinoma (HCC) among veterans differs according to demographic and clinical characteristics, with the lowest rate seen among Asians, reports a study.

17 Aug 2024

Cabozantinib offers survival benefits to ICI-treated HCC patients

11 Aug 2024

A phase II trial of cabozantinib demonstrates the study drug’s efficacy in patients with hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitor (ICI) regimens.

11 Aug 2024

Chế độ ăn ít carbohydrate và giàu protein có thể làm tăng nguy cơ ung thư gan

07 Aug 2024

Theo một nghiên cứu tại Singapore, những người có chế độ ăn giàu chất béo và protein động vật và ít carbohydrate có nguy cơ cao mắc ung thư biểu mô tế bào gan (HCC).

07 Aug 2024

CLD status does not influence MACE risk associated with ticagrelor vs clopidogrel

01 Aug 2024

Use of ticagrelor compared with clopidogrel contributes to a similar risk of major adverse cardiovascular events (MACE) and a higher risk of major bleeding in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), reveals a study.

01 Aug 2024

TOPAZ-1 3-year data reflect long-term survival benefit with durvalumab-chemo in BTC

31 Jul 2024 bởi

In the 3-year updated analysis of the phase III TOPAZ-1 study, the combination of durvalumab and gemcitabine-cisplatin (GC) chemotherapy continues to deliver an overall survival (OS) benefit in individuals with biliary tract cancer (BTC).

31 Jul 2024